GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » EBIT

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) EBIT : E£833 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents EBIT?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was E£313 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was E£833 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROC % for the quarter that ended in Dec. 2024 was 25.67%. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 72.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 10.38%.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents EBIT Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents EBIT Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial 241.75 324.64 417.52 518.65 833.33

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.74 143.70 153.31 223.08 313.23

Competitive Comparison of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EV-to-EBIT falls into.


;
;

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£833 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=1113.924 * ( 1 - 24.46% )/( (2926.963 + 3629.552)/ 2 )
=841.4581896/3278.2575
=25.67 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3591.972 - 354.404 - ( 310.605 - max(0, 1595.418 - 2432.133+310.605))
=2926.963

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4311.316 - 427.372 - ( 254.392 - max(0, 2155.199 - 3137.015+254.392))
=3629.552

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1252.936/( ( (594.393 + max(726.123, 0)) + (621.516 + max(1497.593, 0)) )/ 2 )
=1252.936/( ( 1320.516 + 2119.109 )/ 2 )
=1252.936/1719.8125
=72.85 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(614.224 + 586.931 + -4.5474735088646E-13) - (354.404 + 0 + 120.628)
=726.123

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(817.406 + 845.177 + 478.264) - (427.372 + 0 + 215.882)
=1497.593

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=833.329/8027.643
=10.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents EBIT Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » EBIT
Comparable Companies
CAI:PHAR CAI:MIPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA ITCI SZSE:000538 UTHR BOM:500087 TSE:4507 SHSE:688506 NSE:TORNTPHARM BOM:543904
Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Website
https://www.ramedapharma.com
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the manufacturing, marketing, selling, and storage of pharmaceutical reagents for both human and veterinary use. It is also involved in manufacturing, marketing, selling and storing diagnostic and pharmaceutical reagents for human, veterinary, and diagnostic use.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Headlines

No Headlines